NASDAQ:CCXI - ChemoCentryx Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $33.43
  • Forecasted Upside: 147.44 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.51
▼ -0.02 (-0.15%)
1 month | 3 months | 12 months
Get New ChemoCentryx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CCXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CCXI

Average Price Target: $33.43
▲ +147.44% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ChemoCentryx in the last 3 months. The average price target is $33.43, with a high forecast of $70.00 and a low forecast of $17.00. The average price target represents a 147.44% upside from the last price of $13.51.

Hold

The current consensus among 8 investment analysts is to hold stock in ChemoCentryx. This rating has held steady since February 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/26/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/20/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2021JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Underweight$57.00 ➝ $17.00Low
5/13/2021Stifel NicolausReiterated RatingBuy ➝ Hold$93.00 ➝ $26.00Low
5/13/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$84.00 ➝ $17.00Low
5/13/2021Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$120.00 ➝ $51.00Low
5/12/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$80.00 ➝ $25.00N/A
5/7/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$120.00 ➝ $51.00High
5/7/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$84.00 ➝ $17.00High
5/7/2021Stifel NicolausDowngradeBuy ➝ Hold$93.00 ➝ $26.00High
5/7/2021HC WainwrightLower Price TargetBuy$101.00 ➝ $28.00High
5/7/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$57.00 ➝ $17.00High
5/6/2021Piper SandlerDowngradeOverweight ➝ Neutral$80.00 ➝ $25.00High
5/5/2021Canaccord GenuityReiterated RatingBuyHigh
3/2/2021Raymond JamesBoost Price TargetStrong-Buy$119.00 ➝ $120.00Medium
3/2/2021HC WainwrightBoost Price TargetBuy$83.00 ➝ $101.00Medium
3/1/2021Stifel NicolausInitiated CoverageBuy$93.00Medium
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$100.00 ➝ $119.00Medium
10/29/2020Wells Fargo & CompanyLower Price TargetOverweight$79.00 ➝ $70.00High
10/29/2020Piper SandlerBoost Price TargetOverweight$67.00 ➝ $71.00High
10/29/2020SVB LeerinkBoost Price TargetOutperform$75.00 ➝ $84.00High
10/29/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$63.00 ➝ $60.00High
9/17/2020HC WainwrightBoost Price Target$73.00 ➝ $85.00High
8/12/2020SVB LeerinkBoost Price TargetOutperform$65.00 ➝ $75.00High
8/11/2020Raymond JamesBoost Price TargetStrong-Buy$95.00 ➝ $100.00High
7/29/2020JPMorgan Chase & Co.Lower Price TargetOverweight$64.00 ➝ $61.00Medium
6/16/2020BTIG ResearchInitiated CoverageBuy$70.00Medium
6/3/2020Canaccord GenuityReiterated RatingBuyMedium
5/27/2020Wells Fargo & CompanyInitiated CoverageOverweight$79.00High
5/19/2020Canaccord GenuityLower Price TargetBuy$68.00 ➝ $58.00High
5/18/2020HC WainwrightReiterated RatingBuy$69.00High
5/18/2020Piper SandlerBoost Price TargetReduce ➝ Overweight$54.00 ➝ $70.00High
5/14/2020JPMorgan Chase & Co.Boost Price TargetOverweight$61.00 ➝ $64.00High
5/12/2020Canaccord GenuityBoost Price TargetBuy$64.00 ➝ $68.00High
5/12/2020SVB LeerinkBoost Price TargetOutperform$54.00 ➝ $65.00Medium
5/12/2020Raymond JamesBoost Price TargetStrong-Buy$38.00 ➝ $102.00Medium
5/12/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $69.00High
4/2/2020SVB LeerinkInitiated CoverageBuy$54.00Medium
4/1/2020SVB LeerinkReiterated RatingOutperformHigh
3/11/2020SVB LeerinkReiterated RatingOutperformHigh
3/11/2020JPMorgan Chase & Co.Boost Price TargetOverweight$60.00 ➝ $61.00High
3/11/2020Raymond JamesBoost Price TargetStrong-Buy$56.00 ➝ $64.00High
3/11/2020HC WainwrightReiterated RatingBuyHigh
2/25/2020Canaccord GenuityReiterated RatingBuy ➝ Positive$48.00 ➝ $64.00Medium
2/18/2020JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Positive$28.00 ➝ $60.00High
1/24/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $60.00Low
11/26/2019Raymond JamesBoost Price TargetStrong-Buy$17.00 ➝ $56.00Medium
11/26/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Positive$14.00 ➝ $28.00N/A
11/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$17.00 ➝ $54.00N/A
11/26/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$16.00 ➝ $48.00N/A
11/26/2019HC WainwrightBoost Price TargetBuy ➝ Buy$23.00 ➝ $40.00N/A
10/15/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$16.00 ➝ $14.00High
6/6/2019Raymond JamesLower Price TargetStrong-Buy$24.00 ➝ $17.00High
6/6/2019Canaccord GenuityLower Price TargetBuy$20.00 ➝ $14.00High
5/7/2019HC WainwrightReiterated RatingBuy$23.00High
4/23/2019Raymond JamesSet Price TargetBuy$22.00Low
3/27/2019B. RileyUpgradeNeutral ➝ Buy$12.50 ➝ $22.00High
2/14/2019SVB LeerinkReiterated RatingOutperformN/A
2/11/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$20.00High
1/8/2019B. RileyInitiated CoverageNeutral$12.50Low
11/12/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00High
9/7/2018B. RileyInitiated CoverageNeutral ➝ Neutral$12.50High
8/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$14.00 ➝ $15.00High
8/13/2018HC WainwrightReiterated RatingBuy$20.00High
8/10/2018Canaccord GenuityReiterated RatingBuy$18.00High
6/28/2018Raymond JamesInitiated CoverageStrong-Buy$18.00High
5/16/2018Canaccord GenuityInitiated CoverageBuy$17.00High
5/10/2018CowenReiterated RatingHoldMedium
5/2/2018HC WainwrightInitiated CoverageBuy ➝ Buy$20.00Low
3/13/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$13.00 ➝ $16.00Medium
8/8/2017CowenReiterated RatingHoldHigh
3/15/2017CowenReiterated RatingHoldHigh
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformN/A
8/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$11.00N/A
(Data available from 6/18/2016 forward)
ChemoCentryx logo
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $13.51
Low: $12.79
High: $13.71

50 Day Range

MA: $23.24
Low: $9.59
High: $48.82

52 Week Range

Now: $13.51
Low: $9.53
High: $70.29

Volume

8,370,524 shs

Average Volume

2,009,300 shs

Market Capitalization

$942.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of ChemoCentryx?

The following Wall Street analysts have issued research reports on ChemoCentryx in the last twelve months: Canaccord Genuity, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for CCXI.

What is the current price target for ChemoCentryx?

7 Wall Street analysts have set twelve-month price targets for ChemoCentryx in the last year. Their average twelve-month price target is $33.43, suggesting a possible upside of 147.4%. Wells Fargo & Company has the highest price target set, predicting CCXI will reach $70.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $17.00 for ChemoCentryx in the next year.
View the latest price targets for CCXI.

What is the current consensus analyst rating for ChemoCentryx?

ChemoCentryx currently has 1 sell rating, 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CCXI, but not buy more shares or sell existing shares.
View the latest ratings for CCXI.

What other companies compete with ChemoCentryx?

How do I contact ChemoCentryx's investor relations team?

ChemoCentryx's physical mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company's listed phone number is 650-210-2900 and its investor relations email address is [email protected] The official website for ChemoCentryx is www.chemocentryx.com.